BACKGROUND: To analyze the efficacy of selective laser trabeculoplasty (SLT) on silicone oil-induced secondary glaucoma in terms of intraocular pressure (IOP). PATIENTS AND METHODS: 42 patients (42 eyes) with silicone oil-induced secondary glaucoma were selected, and SLT was performed with 360° of the trabecular meshwork. During the 12-month follow-up, the complications, IOP, and antiglaucoma medication usage were observed. RESULTS: The mean IOP decreased from 23.1 ± 1.9 mmHg before treatment to 18.4 ± 3.7 mmHg after treatment (p < 0.05). Mean number of antiglaucoma medications used for IOP control also decreased from 2.17 ± 1.21 to 1.25 ± 0.89 (p < 0.05). The 12-month success rate in the total sample was 59.5 %. The success rate was 60.7 % (17 eyes) and 57.1 % (eight eyes) for phakic and aphakic eyes, respectively (p > 0.05) CONCLUSIONS: SLT is a safe and effective option for the treatment of patients with silicone oil-induced secondary glaucoma.
BACKGROUND: To analyze the efficacy of selective laser trabeculoplasty (SLT) on silicone oil-induced secondary glaucoma in terms of intraocular pressure (IOP). PATIENTS AND METHODS: 42 patients (42 eyes) with silicone oil-induced secondary glaucoma were selected, and SLT was performed with 360° of the trabecular meshwork. During the 12-month follow-up, the complications, IOP, and antiglaucoma medication usage were observed. RESULTS: The mean IOP decreased from 23.1 ± 1.9 mmHg before treatment to 18.4 ± 3.7 mmHg after treatment (p < 0.05). Mean number of antiglaucoma medications used for IOP control also decreased from 2.17 ± 1.21 to 1.25 ± 0.89 (p < 0.05). The 12-month success rate in the total sample was 59.5 %. The success rate was 60.7 % (17 eyes) and 57.1 % (eight eyes) for phakic and aphakic eyes, respectively (p > 0.05) CONCLUSIONS: SLT is a safe and effective option for the treatment of patients with silicone oil-induced secondary glaucoma.
Authors: Mathew K George; John W Emerson; Sameer A Cheema; Robert McGlynn; Bryce A Ford; James F Martone; Milton Bruce Shields; Martin Wand Journal: J Glaucoma Date: 2008 Apr-May Impact factor: 2.503